NASDAQ:ABSI Absci (ABSI) Stock Price, News & Analysis $4.02 -0.11 (-2.66%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.89▼$4.2150-Day Range$2.97▼$4.4952-Week Range$1.11▼$6.72Volume690,226 shsAverage Volume1.43 million shsMarket Capitalization$454.60 millionP/E RatioN/ADividend YieldN/APrice Target$8.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Absci alerts: Email Address Absci MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside109.0% Upside$8.40 Price TargetShort InterestBearish12.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 2 Articles This WeekInsider TradingSelling Shares$98,898 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.80) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.72 out of 5 starsMedical Sector604th out of 910 stocksCommercial Physical Research Industry8th out of 11 stocks 3.5 Analyst's Opinion Consensus RatingAbsci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbsci has only been the subject of 3 research reports in the past 90 days.Read more about Absci's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.23% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Absci has recently increased by 2.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABSI. Previous Next 2.7 News and Social Media Coverage News SentimentAbsci has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Absci this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows17 people have added Absci to their MarketBeat watchlist in the last 30 days. This is an increase of 143% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Absci insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,898.00 in company stock.Percentage Held by InsidersOnly 9.81% of the stock of Absci is held by insiders.Percentage Held by Institutions52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Absci's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.80) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Absci's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Absci Stock (NASDAQ:ABSI)Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Read More ABSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABSI Stock News HeadlinesAugust 31, 2024 | msn.comAbsci Corporation (ABSI): A Penny Stock That Will Make You a MillionaireAugust 21, 2024 | globenewswire.comAbsci to Participate in Upcoming Investor ConferencesSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 19, 2024 | msn.comAbsci Corporation (NASDAQ:ABSI) Q2 2024 Earnings Call TranscriptAugust 17, 2024 | finance.yahoo.comAbsci Second Quarter 2024 Earnings: Misses ExpectationsAugust 16, 2024 | bizjournals.comAbsci CEO details Sloan Kettering Cancer Center partnershipAugust 16, 2024 | markets.businessinsider.comBuy Rating Justified by ABS-101’s Market Potential and Strategic PartnershipsAugust 15, 2024 | markets.businessinsider.comABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q2 2024September 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 14, 2024 | globenewswire.comAbsci Reports Business Updates and Second Quarter 2024 Financial and Operating ResultsAugust 12, 2024 | globenewswire.comAbsci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AIAugust 5, 2024 | ca.finance.yahoo.comABSI Aug 2024 6.000 putJuly 31, 2024 | msn.comWhy Is Absci Corporation (ABSI) Among the Best Micro Cap Stocks Right Now?July 10, 2024 | globenewswire.comAbsci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024July 3, 2024 | globenewswire.comAbsci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 28, 2024 | globenewswire.comAbsci to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 16, 2024 | seekingalpha.comAbsci: 'AI' Tag Keeping Company Afloat While Searching For Right FormulaMay 16, 2024 | investorplace.com7 Pharma Stocks Harnessing AI Brainpower for Big BreakthroughsSee More Headlines Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:ABSI CUSIPN/A CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$8.40 High Stock Price Target$13.00 Low Stock Price Target$6.00 Potential Upside/Downside+109.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,570,000.00 Net Margins-2,838.89% Pretax Margin-2,836.00% Return on Equity-44.24% Return on Assets-37.50% Debt Debt-to-Equity Ratio0.01 Current Ratio6.49 Quick Ratio6.49 Sales & Book Value Annual Sales$3.25 million Price / Sales139.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book2.06Miscellaneous Outstanding Shares113,084,000Free Float101,990,000Market Cap$454.60 million OptionableOptionable Beta2.21 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Sean McClain (Age 33)Founder, CEO, President & Director Comp: $936.2kDr. Zachariah Jonasson Ph.D. (Age 50)Chief Business Officer & CFO Comp: $98.3kDr. Andreas Busch Ph.D. (Age 61)Chief Innovation Officer & Member of Scientific Advisory Board Comp: $1.56MMr. Todd Bedrick CPASenior VP & Chief Accounting OfficerMr. Alexander Khan CPAVP of Finance & Head of Investor RelationsMs. Karin WierinckChief People OfficerMelissa Patterson Ph.D.Chief of StaffJens Plassmeier Ph.D.Senior VP of Biologics Discovery TechnologyMr. Wen ShaChief of StaffDr. Christine Lemke D.V.M.M.B.A., Ph.D., Senior Vice President of Portfolio & Growth StrategyMore ExecutivesKey CompetitorsHarpoon TherapeuticsNASDAQ:HARPSutro BiopharmaNASDAQ:STROAdaptimmune TherapeuticsNASDAQ:ADAPTScan TherapeuticsNASDAQ:TCRXZymergenNASDAQ:ZYView All CompetitorsInsiders & InstitutionsDeerfield Management Company L.P. Series CBought 135,652 shares on 8/15/2024Ownership: 0.162%The Manufacturers Life Insurance Company Bought 32,529 shares on 8/15/2024Ownership: 0.029%Fred Alger Management LLCSold 151,034 shares on 8/14/2024Ownership: 6.417%Squarepoint Ops LLCBought 155,007 shares on 8/14/2024Ownership: 0.326%Bank of Montreal CanBought 167,959 shares on 8/14/2024Ownership: 0.149%View All Insider TransactionsView All Institutional Transactions ABSI Stock Analysis - Frequently Asked Questions How have ABSI shares performed this year? Absci's stock was trading at $4.20 on January 1st, 2024. Since then, ABSI shares have decreased by 4.3% and is now trading at $4.02. View the best growth stocks for 2024 here. How were Absci's earnings last quarter? Absci Co. (NASDAQ:ABSI) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.03. The firm had revenue of $1.27 million for the quarter, compared to analyst estimates of $2.05 million. Absci had a negative net margin of 2,838.89% and a negative trailing twelve-month return on equity of 44.24%. When did Absci IPO? Absci (ABSI) raised $200 million in an IPO on Thursday, July 22nd 2021. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Who are Absci's major shareholders? Absci's top institutional investors include Fred Alger Management LLC (6.42%), ARK Investment Management LLC (4.87%), Marshall Wace LLP (1.62%) and Sumitomo Mitsui Trust Holdings Inc. (0.65%). Insiders that own company stock include Phoenix Venture Partners Ii Lp, Redmile Group, Llc, Zachariah Jonasson, Todd Bedrick, Sean Mcclain and Sarah Korman. View institutional ownership trends. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABSI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Absci With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.